NCT03831438View on ClinicalTrials.gov

Safety and Tolerability Study of AVID200 in Pts With Diffuse Cutaneous Systemic Sclerosis

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

January 1, 2019

Primary Completion Date

June 20, 2020

Study Completion Date

June 20, 2020

Conditions
Scleroderma, Diffuse
Interventions
DRUG

AVID200

Intravenous infusion of AVID200 Q2 weeks for 3 doses

Trial Locations (4)

10035

Hospital of Special Surgery, New York

15213

University of Pittsburgh Medical Center, Pittsburgh

19104

University of Pennsylvania, Philadelphia

90095

UCLA, Los Angeles

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT03831438 - Safety and Tolerability Study of AVID200 in Pts With Diffuse Cutaneous Systemic Sclerosis | Biotech Hunter | Biotech Hunter